Search clinical trials for: Alpha Interferon

Total 8015 results

Markus Peck-Radosavljevic
Medical University of Vienna

Completed

Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C (HIVCOBOC-RGT)

Hepatitis C, Chronic | HIV

Austria
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer

Pancreatic Cancer

United States
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Terminated

Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer

Cervical Cancer

United States
Peking University People's Hospital

Unknown

Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT

Acute Myeloid Leukemia

China
M.D. Anderson Cancer Center
Novartis

Completed

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

Leukemia, Myeloid, Chronic

United States
Merck Sharp & Dohme LLC

Completed

Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC
Bioikos Ambiente Srl

Completed

Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)

Hepatitis C
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine

Melanoma

United States
Bristol-Myers Squibb

Completed

BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C

Hepatitis C

United States, Puerto Rico
King Abdulaziz Medical City
King Faisal Specialist Hospital & Research Center; Riyadh Military Hospital

Completed

Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients

Chronic Hepatitis C | Renal Transplant

Saudi Arabia
M.D. Anderson Cancer Center
Eisai Inc.

Terminated

Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Minneapolis Veterans Affairs Medical Center
US Department of Veterans Affairs; Kadmon Corporation, LLC; InterMune; San Diego... and other collaborators

Completed

Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial

Chronic Hepatitis C
Shanghai Zhongshan Hospital

Recruiting

Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC

Hepatocellular Carcinoma

China
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC

Terminated

Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis

Myelofibrosis

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid Leukemia

Leukemia

United States
Fremantle Hospital and Health Service

Completed

In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia

Hepatitis C

Australia
Boehringer Ingelheim

Completed

Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)

Hepatitis C

United States, Austria, Canada, France, Germany, Romania
Queen Mary University of London
Nottingham University Hospitals NHS Trust; Barts & The London NHS Trust; Janssen-Cilag... and other collaborators

Completed

Telaprevir in Genotype 3 HCV (TIG3)

Hepatitis C

United Kingdom
John Kirkwood
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma (12-107)

Melanoma

United States
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)

Completed

Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Bristol-Myers Squibb

Completed

Ph IIA Study (SOC +/- NS5B) (HEPCAT)

Hepatitis C Virus

United States
University of Calgary
Canadian Institutes of Health Research (CIHR); Roche Pharma AG

Completed

Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C

Hepatitis c

Canada
Kirby Institute
National Institutes of Health (NIH); The University of New South Wales

Completed

Australian Trial in Acute Hepatitis C

Hepatitis C

Australia
M.D. Anderson Cancer Center
Schering-Plough

Completed

PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML

Chronic Myeloid Leukemia

United States
Lisa H. Butterfield, Ph.D.
National Cancer Institute (NCI)

Completed

Multiple Antigen-Engineered DC Vaccine for Melanoma

Melanoma

United States
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

Hepatitis C, Chronic

United States, Austria, Belgium, Canada, France, Germany, Japan, Portugal, Puerto Rico, Spain, Switzerland, United Kingdom
Case Comprehensive Cancer Center

Completed

Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance

Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Recurrent Intraocular Melanoma

United States
National Cancer Institute (NCI)

Terminated

Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma

United States
Peter MacCallum Cancer Centre, Australia

Completed

COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; (C-SMART)

Cancer | Covid19 | Respiratory Viral Infection

Australia
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

Malignant Mesothelioma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer

Bladder Cancer

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer

Lung Cancer

United States
ANRS, Emerging Infectious Diseases
Institut Pasteur

Withdrawn

Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C (ViZIR)

Chronic Hepatitis C

Egypt
GlaxoSmithKline
PPD

Completed

Dose Ranging of GSK2336805 in Combination Therapy (HAI115879)

Hepatitis C, Chronic

Puerto Rico, United States, Bulgaria, Germany, Belgium, France
Leiden University Medical Center
University Medical Center Groningen

Completed

Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer (PITCH)

Recurrent Ovarian Cancer

Netherlands
M.D. Anderson Cancer Center
Vertex Pharmaceuticals Incorporated

Terminated

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

Infection

United States
Hospices Civils de Lyon
Novartis

Unknown

Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients (PETALs)

Chronic Myeloid Leukemia

France
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C

Chronic Hepatitis C

Austria, France, Germany, United Kingdom
Bausch Health Americas, Inc.

Completed

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive (VISER2)

Chronic Hepatitis C

United States, Spain, Italy, Australia, Canada, Poland, Puerto Rico, Russian Federation, Argentina, France, Israel, United Kingdom
University of Turin, Italy

Unknown

Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels

Chronic Hepatitis C

Italy
European Organisation for Research and Treatment...

Completed

Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer

Kidney Cancer

Switzerland, Netherlands, Norway, Belgium, United Kingdom, Hungary, Italy, Turkey, Russian Federation
Peking University People's Hospital

Withdrawn

Interferon-α Prevents Leukemia Relapse of AML Patients After Transplantation

Relapse | Prevention | Interferon-A-2B | Hematopietic Stem Cell Transplantation

China
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma

HIV Infections | Sarcoma, Kaposi

United States
Brooke Army Medical Center
T.R.U.E. Research Foundation

Completed

Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC

Hepatitis C

United States
Sociedad Andaluza de Enfermedades Infecciosas

Completed

Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients (SAEI_IFN_1)

HIV Infections | Hepatitis C, Chronic

Spain
Sheba Medical Center

Unknown

Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.

Chronic Hepatitis C
Leiden University
Bristol-Myers Squibb

Active, not recruiting

TIL and Anti-PD1 in Metastatic Melanoma (ACTME)

Effects of Immunotherapy | Adverse Drug Event | Toxicity, Drug

Netherlands
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C

Chronic Hepatitis C

Taiwan
Merck Sharp & Dohme LLC

Terminated

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)

Melanoma

Search clinical trials for: Alpha Interferon

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations